Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
about
The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workersA case-only analysis of the interaction between N-acetyltransferase 2 haplotypes and tobacco smoke in breast cancer etiology.Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome.Inferring haplotypes at the NAT2 locus: the computational approach.Pharmacogenomics in the clinicArylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discoveryN-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic aminesArylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitroPolymorphism of human acetyltransferasesThe Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and MetabolismMitochondrial DNA (mtDNA) haplotypes and dysfunctions in presbyacusisGenotyping panel for assessing response to cancer chemotherapy.Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.Relationship between N-acetyltransferase 2 single-nucleotide polymorphisms and phenotype.Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?Genetic susceptibility to tobacco carcinogenesis.Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk.Antioxidant enzymes, presbycusis, and ethnic variability.Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes.Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women.Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.Candidate gene approach for pharmacogenetic studies.Pharmacogenetics of the arylamine N-acetyltransferases.Racial, ethnic, and gender variations in cancer risk: considerations for future epidemiologic research.Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesisBiomarkers in occupational cancer epidemiology: considerations in study design.DNA arrays as diagnostic tools in human healthcare.N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium: proposal for a common catalytic mechanism of arylamine acetyltransferase enzymes.Clinically relevant genetic variations in drug metabolizing enzymes.Pharmacogenetics: the slow, the rapid, and the ultrarapid.Pharmacogenomics: marshalling the human genome to individualise drug therapyArylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activityA cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymesAccuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.Personalizing medicine with clinical pharmacogeneticsPossible implications of doxycycline-rifampin interaction for treatment of brucellosisPharmacogenetic approaches to rheumatoid arthritis.N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions.Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
P2860
Q23923016-29FB238E-5483-46FA-A865-9A25576744EBQ24810267-85F52940-5EA4-4A38-B1D1-D850F8996D7FQ24812002-CB0B23EC-7278-4E69-993E-E6B49D9AEF37Q24815593-23D79777-484F-4AA3-B4A3-87EAAC47B7A5Q26782786-A9D21C7E-1195-4C43-832B-51CDD6B1B412Q26995125-92F5F5BC-502C-486B-9CE2-33D164186948Q28388128-C5A3E11D-D4B9-48EF-8303-9200DAF73A2DQ28391158-0D5791A6-F8BB-42CB-909E-E77FF0D1D760Q28512216-91DB8371-0D85-4B2F-ADCB-8807FE8F487CQ28646030-2AF6D20C-3C62-4DC4-8D45-41497F224C25Q28822540-5738C7AB-94C1-46E3-81BD-A866794F5271Q30440444-474F1A50-AA98-484B-84E3-B0E62A5712C9Q33343095-4669F075-0E02-42DF-A42E-80822B8D69C3Q33538523-6D833595-8BC9-4044-8D0E-48D7D329EC22Q33615327-B7CC6580-8FA2-4E79-AECC-8539FAF98B5BQ33770163-DC588178-09E9-4014-943C-788460D72DD0Q33791708-5B2AA524-089A-4D3B-B75B-9FFAA4784BC4Q33921738-36149ADE-A22C-46A0-899B-978D8CC98559Q34033684-9F9AED86-27E6-453A-893F-52AC970DE8E6Q34035249-E0D2A92D-3E77-44A5-8B2E-B56E81D52EBCQ34044101-F7654D66-3E79-45C3-A6DE-87A90690362CQ34311814-F705EC22-6574-4C22-BCC7-C52F5D26702EQ34609133-C00AD2B7-F9D3-45C3-8D9B-F0197DF5D4A7Q34624647-6EB576F4-2EF3-4114-BCB2-95C248CAF0C0Q34834089-37696B7B-CE99-408E-BFC3-EB8D0BF1E3FBQ34844333-E60133EF-2C8A-46DE-B74A-B7163A0C3037Q34844405-68C0E59E-0F03-4C57-BB6A-DCFD83C4D589Q34884635-DDCAB589-AE10-4307-A722-3F97461BE870Q35030969-3CDF4FD1-3D2C-4D2F-B735-AEED7BB6B94AQ35032378-78313189-DE96-4B6F-B909-6B4EC506DC8FQ35085298-FDE0FC3A-73D7-4048-90A2-5D7D3BF8E004Q35090217-6DFFED94-6AEB-4468-8075-152398140BE2Q35643631-8288B238-B38E-4BC6-8006-95763B016892Q35647066-249476CC-3731-44FF-A51B-C902ED5CB70FQ35774965-3B39B53A-D1E2-4961-A51F-918FA619E2BFQ35791989-48E1CD54-787A-4D8C-90D3-59DF8C2EB88AQ35823142-28AB6813-E497-4573-9A6B-A26E97C9BA87Q35834289-66BECD98-1ED5-4AFD-B363-E34F44043698Q35840959-8E5E86C9-EB02-47A2-BC6F-78EF4B156569Q35846717-EEF98826-955E-4980-92FD-D1FC9972391B
P2860
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
@en
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
@nl
type
label
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
@en
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
@nl
prefLabel
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
@en
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
@nl
P2093
P2860
P356
P1476
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
@en
P2093
P2860
P304
P356
10.1073/PNAS.88.12.5237
P407
P577
1991-06-01T00:00:00Z